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Summary  
The World Health Organization European Region has one of the highest rates of multidrug-resistant (MDR) 
tuberculosis (TB) in the world, resulting in many vulnerable children getting exposed each year. Evidence for 
preventive therapy following MDR-TB exposure is limited and current guidance is conflicting. An online 
survey was performed to determine clinical practice in this region. Seventy-two clinicians from 25 countries 
participated. Practices related to screening and decision-making were highly variable. Just over half were 
providing preventive therapy for MDR-TB-exposed children; the only characteristic associated with provision 
was practice within the European Union (adjusted odds ratio: 4.07; 95% confidence interval: 1.33-12.5). 
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Background 
Multidrug-resistant (MDR) tuberculosis (TB) is caused by Mycobacterium tuberculosis with resistance to 
isoniazid and rifampicin.1 In the World Health Organization (WHO) European Region (defined at: 
http://www.who.int/about/regions/euro/en/) 16% of new TB cases and 48% of retreatment cases were 
estimated to be MDR-TB in 2015.2 Over 40,000 cases were notified that year,2 many of whom had contact 
with children. Young children are at high risk of progression to TB, including MDR-TB, following exposure.3,4 
MDR-TB treatment is long, expensive and associated with significant adverse events.  
 
There is good evidence for the effectiveness of drug therapy for child contacts of drug-susceptible TB to 
prevent progression to TB disease.5 However, the evidence base for the management of child contacts of 
MDR-TB cases is less robust. National and international guidance is inconsistent and conflicting, with 
clinicians facing difficult management choices. To date, only limited data exist regarding the current 
management of paediatric MDR-TB contacts in clinical practice. We therefore aimed to document current 
practice across different countries in the WHO European Region. 
 
 
Methods 
From March-July 2014 a web-based survey was conducted to explore variations in the management of MDR-
TB-exposed children.6 We developed an online questionnaire in English and Russian capturing the following: 
respondent characteristics, screening practices, preventive therapy (PT) practices, and follow-up 
(Supplementary Materials). Participants were asked to define patient groups considered for PT, the PT 
regimens used and treatment duration. The questionnaire was piloted among five clinical experts within the 
Paediatric Tuberculosis Network European Trials Group (ptbnet).7   
 
A list of clinicians likely to be managing child MDR-TB contacts in the WHO European Region was compiled 
using the membership lists of ptbnet, the International Union Against Tuberculosis and Lung Disease 
Childhood TB Working Group, and the Childhood Subgroup of the WHO Stop TB Partnership. Each clinician 
was sent a personalised email requesting their participation, with the request to forward the invitation to 
relevant colleagues. Three reminder emails were sent during the study period (Supplementary Materials).  
To assess factors associated with PT provision, we used a multivariable stepwise logistic regression model. 
Variables with p<0.15 in the univariable analysis were included in the model. Statistical analyses were 
undertaken using Stata version 14.0 (StataCorp, College Station, U.S.). 
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Ethics Approval 
Under current UK National Research Ethics Service (NRES) regulations, Research Ethics Committee review is 
not required for research involving healthcare staff recruited as research participants by virtue of their 
professional role (Governance Arrangements for Research Ethics Committees, paragraph 2.3.13). 
Participation in the survey was voluntary. Participants were aware that they were participating in research, 
and that the results may be published.  
 
Results 
Of 176 specialists from 44 countries approached, 72 (41%) respondents from 25 countries participated in the 
survey, including 28 from 6 countries outside the EU/EEA (Figure 1). Of all respondents, 66/72 (92%) had >5 
years of experience working with TB; 59/72 (82%) were at senior level and 41/72 (57%) managed ≥3 child 
MDR-TB contacts a year. To guide the management of the contacts, in addition to clinical history and 
examination, most respondents used imaging: 42/72 (58%) chest x-rays, 21/72 (29%) both chest x-rays and 
computer tomography, 4/72 (6%) computer tomography only; the remaining 5/72 (7%) did not routinely use 
imaging. Nearly half (32/72;44%) stated routinely collecting respiratory specimens in asymptomatic children. 
Variable combinations of interferon-gamma release assays (IGRA) and skin tests were used to diagnose TB 
infection: 45/72 (63%) used both IGRA and skin tests, 23/72 (32%) skin tests only, 2/72 (3%) IGRA only and 
2/72 (3%) neither. Of the skin tests, the tuberculin skin test (TST) was most frequently used; the Diaskintest 
(using recombinant CFP-10/ESAT-6; Generium Pharmaceuticals, Moscow) was used by 11 respondents based 
in the Russian Federation, Belarus, Estonia and Ukraine. 
  
Of all 72 respondents, 42 (58%) stated they were providing PT to MDR-TB-exposed children. For children 
with evidence of TB infection, 18/42 (43%) clinicians were providing PT if additional risk factors were present 
(age <2 or <5 years, HIV-infection or immunocompromise); 24/42 (57%) were treating all TB-infected 
children. For children without evidence of TB infection, the majority of respondents (26/42;62%) were doing 
follow-up without PT, 12/42 (29%) were providing PT if risk factors were present, and 4/42 (10%) were 
treating all contacts. For PT, 31/42 (74%) used regimens tailored to the drug susceptibility pattern of the 
source case’s isolate, 9/42 (21%) used standardised regimens (i.e. independent of susceptibility results), and 
two used variable approaches depending on situation. Approximately half of the respondents (22/42;52%) 
were using two-drug regimens, fewer used 3 drugs (8/42;19%) or monotherapy (10/42;24%), and the 
remaining two decided on case by case. Variable combinations of ethambutol, pyrazinamide, high-dose 
isoniazid and levofloxacin/moxifloxacin were the most commonly reported regimens. Most respondents 
(30/42;71%) stated treating for 6 or 9 months (50% and 21%, respectively). Most clinicians were following 
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children up for two years or longer regardless of PT being used or not (30/42;71% and 61/72;85% 
respectively) (Supplementary Materials). 
 
In the multivariable model the only factor associated with the provision of PT was practice within the EU/EEA 
(vs. outside the EU/EEA) with an adjusted odds ratio of 4.07 (95% CI: 1.33-12.5; p=0.014; Table 1). 
 
 
Discussion and Conclusions 
The results highlight a wide spectrum of practice in the management of children exposed to MDR-TB in 
countries of the WHO European Region. Over half of clinicians reported using PT with varying indications and 
drug regimens. Practices regarding PT differed significantly between clinicians based within the EU/EEA and 
those based outside. The observed difference between EU/EAA and non-EU countries may be due to a more 
individualised approach to patient management in EU/EAA countries versus a more programmatic approach 
in non-EU countries with greater reliance on official national guidelines and WHO recommendations. 
 
In addition to marked heterogeneity regarding provision of PT, our data also indicate high variation in 
investigations performed in children with MDR-TB contact with somewhat surprisingly high proportion of CT 
scans and collection of respiratory specimens in asymptomatic children. These findings may be a reflection 
of the paucity of data to guide standard diagnostic approaches in these children, and indicate that clinicians 
may have a tendency for more ‘aggressive’ investigation strategies in MDR-TB contacts.   
 
A key component of the WHO End TB Strategy is the identification and treatment of TB infection,8 with 
modelling exercises suggesting that without addressing TB infection it will be impossible to eliminate TB 
globally.9 This is as true, if not more so, for MDR-TB as it is for drug-susceptible TB, as a smaller proportion of 
MDR-TB cases are identified and treated, and outcomes are much poorer. At least three funded trials 
investigating the treatment of MDR-TB contacts are currently underway, but results are not expected for 
several years. Observational studies suggest that the use of PT for MDR-TB can be safe and effective,10 but 
existing guidelines are highly variable. It is therefore not surprising that current practice across the WHO 
European Region is so inconsistent, and it appears likely that these inconsistencies will persist until 
international and national guidelines are harmonised. 
 
The survey was limited to clinicians managing child MDR-TB contacts in the WHO European Region who were 
identified and responded to the survey. Although we contacted a wide range of clinicians and included 
flexible answer options, it is likely that not all possible practices were captured. The survey only documents 
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reported practice, rather than capturing individual patient management. Despite these limitations, the 
results provide insight into the current management of paediatric MDR-TB contacts in EU/EAA and non-EU, 
countries and highlight the urgent need for stronger evidence to guide clinical decisions.   
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Table 1. Association between respondent characteristics and the provision of preventive therapy (n=72) 1 
 PT  
given  
(n) 
PT  
not given 
(n) 
Odds ratio  
(95% CI) 
P value Adjusted Odds ratio  
(95% CI) 
P value 
Experience of treating TB 
patients 
<10 years 13 10 Ref 0.83   
≥ 10 years 29 20 1.12 (0.41-3.06)    
Specialist TB doctor 
No 28 13 Ref 
0.05 
Ref 
0.51 
Yes 14 17 0.38 (0.14-1.04) 0.69 (0.23-2.09) 
Consultant level doctor 
No 6 7 Ref 
0.33 
 
 
Yes 36 23 1.83 (0.54-6.22)  
Number of MDR-TB child 
contacts managed per year 
<3 per year 19 12 Ref 0.66   
≥3 per year 23 18 0.81 (0.31-2.10)    
Country of respondent 
Outside EU/EEA 10 18 Ref 
0.002 
Ref 
0.014 
Within EU/ EEA 32 12 4.80 (1.59-14.5) 4.07 (1.33-12.5) 
CI: confidence interval; EEA: European Economic Area; MDR-TB: multidrug-resistant tuberculosis; PT: preventive therapy Ref: reference value; TB: 2 
tuberculosis. 3 
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Figure 1 11 
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Figure Legend 13 
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Figure 1: Location of practice and number of survey respondents in countries in the World Health 15 
Organization European Region. Participating countries: Albania, Armenia, Austria, Belarus, Belgium, 16 
Bulgaria, Estonia, Finland, Germany, Greece, Ireland, Israel, Latvia, Lithuania, Malta, Moldova, Portugal, 17 
Romania, Russian Federation, Spain, Sweden, Switzerland, Tajikistan, UK, Ukraine 18 
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